Ensayos clínicos

Inclusion Criteria

• History of culture positive mycobacterial disease or refractory EP-NTM disease that has indicated resistance to first line agents and sensitivity to Clofazimine, or an additional drug needs to be added to the regimen because of inadequate response to existing therapy
• History of culture positive mycobacterial disease that is sensitive to Clofazimine, and has experienced an allergic or adverse reaction to other agents that prevent their use
• Clinical disease that has responded to treatment with antimycobacterial drugs but experienced allergic or adverse reactions to these agents that has prevented continued use or experienced a relapse in disease that necessitates the addition, or substitution, of second-line agents
• Has signed an informed consent

Exclusion Criteria

• Mycobacterial disease can be adequately treated by other available medications
• Allergy or a severe adverse reaction to Clofazimine in the past
• Is unable or unwilling to sign the informed consent
• Life expectancy of less than 6 months
• Unable to swallow capsules
• Has HIV infection